nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM3—epilepsy syndrome	0.113	0.371	CbGaD
Solifenacin—CHRM1—epilepsy syndrome	0.106	0.346	CbGaD
Solifenacin—multiple sclerosis—Diazepam—epilepsy syndrome	0.0867	0.213	CpDpCtD
Solifenacin—multiple sclerosis—Oxcarbazepine—epilepsy syndrome	0.0867	0.213	CpDpCtD
Solifenacin—CHRM2—epilepsy syndrome	0.0863	0.283	CbGaD
Solifenacin—multiple sclerosis—Pregabalin—epilepsy syndrome	0.0737	0.181	CpDpCtD
Solifenacin—multiple sclerosis—Carbamazepine—epilepsy syndrome	0.0657	0.161	CpDpCtD
Solifenacin—multiple sclerosis—Clonazepam—epilepsy syndrome	0.0525	0.129	CpDpCtD
Solifenacin—multiple sclerosis—Gabapentin—epilepsy syndrome	0.0423	0.104	CpDpCtD
Solifenacin—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0113	0.0879	CbGbCtD
Solifenacin—CYP3A4—Trimethadione—epilepsy syndrome	0.0105	0.0817	CbGbCtD
Solifenacin—CYP3A4—Felbamate—epilepsy syndrome	0.0105	0.0817	CbGbCtD
Solifenacin—CYP3A4—Fosphenytoin—epilepsy syndrome	0.0099	0.0768	CbGbCtD
Solifenacin—CYP3A4—Clonazepam—epilepsy syndrome	0.00895	0.0694	CbGbCtD
Solifenacin—CYP3A4—Clobazam—epilepsy syndrome	0.00858	0.0666	CbGbCtD
Solifenacin—CYP3A4—Rufinamide—epilepsy syndrome	0.0073	0.0566	CbGbCtD
Solifenacin—CYP3A4—Carbamazepine—epilepsy syndrome	0.00711	0.0552	CbGbCtD
Solifenacin—CYP3A4—Primidone—epilepsy syndrome	0.00664	0.0515	CbGbCtD
Solifenacin—CYP3A4—Phenytoin—epilepsy syndrome	0.00638	0.0495	CbGbCtD
Solifenacin—CYP3A4—Propofol—epilepsy syndrome	0.00595	0.0462	CbGbCtD
Solifenacin—CYP3A4—Acetazolamide—epilepsy syndrome	0.00568	0.0441	CbGbCtD
Solifenacin—CYP3A4—Phenobarbital—epilepsy syndrome	0.00568	0.0441	CbGbCtD
Solifenacin—CYP3A4—Midazolam—epilepsy syndrome	0.00561	0.0435	CbGbCtD
Solifenacin—CYP3A4—Diazepam—epilepsy syndrome	0.00539	0.0418	CbGbCtD
Solifenacin—CYP3A4—Zonisamide—epilepsy syndrome	0.00526	0.0408	CbGbCtD
Solifenacin—CYP3A4—Valproic Acid—epilepsy syndrome	0.00425	0.033	CbGbCtD
Solifenacin—CYP3A4—Topiramate—epilepsy syndrome	0.00383	0.0297	CbGbCtD
Solifenacin—Mequitazine—CHRM2—epilepsy syndrome	0.000286	0.686	CrCbGaD
Solifenacin—CHRM4—head—epilepsy syndrome	0.000188	0.0589	CbGeAlD
Solifenacin—CHRM4—nervous system—epilepsy syndrome	0.000178	0.0558	CbGeAlD
Solifenacin—CHRM2—forebrain—epilepsy syndrome	0.000176	0.0552	CbGeAlD
Solifenacin—CHRM4—central nervous system—epilepsy syndrome	0.000172	0.0538	CbGeAlD
Solifenacin—CHRM2—telencephalon—epilepsy syndrome	0.000162	0.0508	CbGeAlD
Solifenacin—CHRM1—forebrain—epilepsy syndrome	0.000161	0.0502	CbGeAlD
Solifenacin—CHRM1—telencephalon—epilepsy syndrome	0.000148	0.0462	CbGeAlD
Solifenacin—CHRM5—head—epilepsy syndrome	0.000147	0.046	CbGeAlD
Solifenacin—CHRM3—forebrain—epilepsy syndrome	0.000144	0.045	CbGeAlD
Solifenacin—CHRM5—nervous system—epilepsy syndrome	0.000139	0.0436	CbGeAlD
Solifenacin—CHRM4—brain—epilepsy syndrome	0.000136	0.0427	CbGeAlD
Solifenacin—CHRM5—central nervous system—epilepsy syndrome	0.000134	0.042	CbGeAlD
Solifenacin—CHRM3—telencephalon—epilepsy syndrome	0.000132	0.0413	CbGeAlD
Solifenacin—Mequitazine—CYP2D6—epilepsy syndrome	0.000131	0.314	CrCbGaD
Solifenacin—CHRM5—brain—epilepsy syndrome	0.000107	0.0334	CbGeAlD
Solifenacin—CHRM2—head—epilepsy syndrome	0.000101	0.0316	CbGeAlD
Solifenacin—CHRM2—nervous system—epilepsy syndrome	9.58e-05	0.03	CbGeAlD
Solifenacin—CHRM2—central nervous system—epilepsy syndrome	9.22e-05	0.0288	CbGeAlD
Solifenacin—CHRM1—head—epilepsy syndrome	9.19e-05	0.0288	CbGeAlD
Solifenacin—CHRM1—nervous system—epilepsy syndrome	8.72e-05	0.0273	CbGeAlD
Solifenacin—CHRM1—central nervous system—epilepsy syndrome	8.39e-05	0.0263	CbGeAlD
Solifenacin—CHRM3—head—epilepsy syndrome	8.23e-05	0.0257	CbGeAlD
Solifenacin—CHRM3—nervous system—epilepsy syndrome	7.8e-05	0.0244	CbGeAlD
Solifenacin—CHRM3—central nervous system—epilepsy syndrome	7.51e-05	0.0235	CbGeAlD
Solifenacin—CHRM2—brain—epilepsy syndrome	7.32e-05	0.0229	CbGeAlD
Solifenacin—CHRM1—brain—epilepsy syndrome	6.66e-05	0.0208	CbGeAlD
Solifenacin—CHRM3—brain—epilepsy syndrome	5.96e-05	0.0187	CbGeAlD
Solifenacin—Nausea—Acetazolamide—epilepsy syndrome	5.24e-05	0.000519	CcSEcCtD
Solifenacin—Dizziness—Levetiracetam—epilepsy syndrome	5.24e-05	0.000519	CcSEcCtD
Solifenacin—Feeling abnormal—Carbamazepine—epilepsy syndrome	5.23e-05	0.000518	CcSEcCtD
Solifenacin—Abdominal pain—Oxcarbazepine—epilepsy syndrome	5.23e-05	0.000518	CcSEcCtD
Solifenacin—Cough—Valproic Acid—epilepsy syndrome	5.22e-05	0.000517	CcSEcCtD
Solifenacin—Vomiting—Propofol—epilepsy syndrome	5.21e-05	0.000516	CcSEcCtD
Solifenacin—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	5.19e-05	0.000514	CcSEcCtD
Solifenacin—Pruritus—Diazepam—epilepsy syndrome	5.19e-05	0.000514	CcSEcCtD
Solifenacin—Urinary tract infection—Topiramate—epilepsy syndrome	5.19e-05	0.000513	CcSEcCtD
Solifenacin—Rash—Propofol—epilepsy syndrome	5.17e-05	0.000512	CcSEcCtD
Solifenacin—Dermatitis—Propofol—epilepsy syndrome	5.17e-05	0.000511	CcSEcCtD
Solifenacin—Hypertension—Valproic Acid—epilepsy syndrome	5.16e-05	0.000511	CcSEcCtD
Solifenacin—Immune system disorder—Gabapentin—epilepsy syndrome	5.14e-05	0.000509	CcSEcCtD
Solifenacin—Headache—Propofol—epilepsy syndrome	5.14e-05	0.000509	CcSEcCtD
Solifenacin—Mediastinal disorder—Gabapentin—epilepsy syndrome	5.13e-05	0.000508	CcSEcCtD
Solifenacin—Hypersensitivity—Zonisamide—epilepsy syndrome	5.12e-05	0.000507	CcSEcCtD
Solifenacin—Vomiting—Midazolam—epilepsy syndrome	5.1e-05	0.000505	CcSEcCtD
Solifenacin—Asthenia—Felbamate—epilepsy syndrome	5.1e-05	0.000505	CcSEcCtD
Solifenacin—Vision blurred—Pregabalin—epilepsy syndrome	5.09e-05	0.000504	CcSEcCtD
Solifenacin—Feeling abnormal—Lamotrigine—epilepsy syndrome	5.06e-05	0.000501	CcSEcCtD
Solifenacin—Rash—Midazolam—epilepsy syndrome	5.06e-05	0.000501	CcSEcCtD
Solifenacin—Dizziness—Fosphenytoin—epilepsy syndrome	5.06e-05	0.000501	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	5.05e-05	0.0005	CcSEcCtD
Solifenacin—Dermatitis—Midazolam—epilepsy syndrome	5.05e-05	0.0005	CcSEcCtD
Solifenacin—Urticaria—Carbamazepine—epilepsy syndrome	5.05e-05	0.0005	CcSEcCtD
Solifenacin—Vomiting—Levetiracetam—epilepsy syndrome	5.04e-05	0.000499	CcSEcCtD
Solifenacin—Headache—Midazolam—epilepsy syndrome	5.03e-05	0.000498	CcSEcCtD
Solifenacin—Pruritus—Felbamate—epilepsy syndrome	5.02e-05	0.000498	CcSEcCtD
Solifenacin—Abdominal pain—Carbamazepine—epilepsy syndrome	5.02e-05	0.000497	CcSEcCtD
Solifenacin—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	5.02e-05	0.000497	CcSEcCtD
Solifenacin—Rash—Levetiracetam—epilepsy syndrome	5e-05	0.000495	CcSEcCtD
Solifenacin—Dermatitis—Levetiracetam—epilepsy syndrome	4.99e-05	0.000494	CcSEcCtD
Solifenacin—Asthenia—Zonisamide—epilepsy syndrome	4.99e-05	0.000494	CcSEcCtD
Solifenacin—Mental disorder—Gabapentin—epilepsy syndrome	4.99e-05	0.000494	CcSEcCtD
Solifenacin—Dry mouth—Valproic Acid—epilepsy syndrome	4.98e-05	0.000493	CcSEcCtD
Solifenacin—Headache—Levetiracetam—epilepsy syndrome	4.96e-05	0.000491	CcSEcCtD
Solifenacin—Malnutrition—Gabapentin—epilepsy syndrome	4.96e-05	0.000491	CcSEcCtD
Solifenacin—Angioedema—Pregabalin—epilepsy syndrome	4.94e-05	0.000489	CcSEcCtD
Solifenacin—Hypersensitivity—Clonazepam—epilepsy syndrome	4.94e-05	0.000489	CcSEcCtD
Solifenacin—Dizziness—Vigabatrin—epilepsy syndrome	4.93e-05	0.000488	CcSEcCtD
Solifenacin—Confusional state—Valproic Acid—epilepsy syndrome	4.92e-05	0.000487	CcSEcCtD
Solifenacin—Pruritus—Zonisamide—epilepsy syndrome	4.92e-05	0.000487	CcSEcCtD
Solifenacin—Hypersensitivity—Phenytoin—epilepsy syndrome	4.9e-05	0.000485	CcSEcCtD
Solifenacin—Anaphylactic shock—Valproic Acid—epilepsy syndrome	4.88e-05	0.000483	CcSEcCtD
Solifenacin—Urticaria—Lamotrigine—epilepsy syndrome	4.88e-05	0.000483	CcSEcCtD
Solifenacin—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	4.88e-05	0.000483	CcSEcCtD
Solifenacin—Nausea—Propofol—epilepsy syndrome	4.87e-05	0.000482	CcSEcCtD
Solifenacin—Vomiting—Fosphenytoin—epilepsy syndrome	4.86e-05	0.000481	CcSEcCtD
Solifenacin—Abdominal pain—Lamotrigine—epilepsy syndrome	4.85e-05	0.000481	CcSEcCtD
Solifenacin—Dysgeusia—Gabapentin—epilepsy syndrome	4.85e-05	0.000481	CcSEcCtD
Solifenacin—Dizziness—Diazepam—epilepsy syndrome	4.85e-05	0.00048	CcSEcCtD
Solifenacin—Infection—Valproic Acid—epilepsy syndrome	4.85e-05	0.00048	CcSEcCtD
Solifenacin—Rash—Fosphenytoin—epilepsy syndrome	4.82e-05	0.000477	CcSEcCtD
Solifenacin—Dermatitis—Fosphenytoin—epilepsy syndrome	4.82e-05	0.000477	CcSEcCtD
Solifenacin—Asthenia—Clonazepam—epilepsy syndrome	4.81e-05	0.000476	CcSEcCtD
Solifenacin—Headache—Fosphenytoin—epilepsy syndrome	4.79e-05	0.000474	CcSEcCtD
Solifenacin—Nervous system disorder—Valproic Acid—epilepsy syndrome	4.78e-05	0.000474	CcSEcCtD
Solifenacin—Palpitations—Pregabalin—epilepsy syndrome	4.78e-05	0.000473	CcSEcCtD
Solifenacin—Asthenia—Phenytoin—epilepsy syndrome	4.77e-05	0.000473	CcSEcCtD
Solifenacin—Nausea—Midazolam—epilepsy syndrome	4.77e-05	0.000472	CcSEcCtD
Solifenacin—Hallucination—Topiramate—epilepsy syndrome	4.76e-05	0.000472	CcSEcCtD
Solifenacin—Tachycardia—Valproic Acid—epilepsy syndrome	4.76e-05	0.000471	CcSEcCtD
Solifenacin—Pharyngitis—Topiramate—epilepsy syndrome	4.75e-05	0.000471	CcSEcCtD
Solifenacin—Asthenia—Oxcarbazepine—epilepsy syndrome	4.75e-05	0.00047	CcSEcCtD
Solifenacin—Pruritus—Clonazepam—epilepsy syndrome	4.74e-05	0.000469	CcSEcCtD
Solifenacin—Vomiting—Vigabatrin—epilepsy syndrome	4.74e-05	0.000469	CcSEcCtD
Solifenacin—Skin disorder—Valproic Acid—epilepsy syndrome	4.74e-05	0.000469	CcSEcCtD
Solifenacin—Urinary tract disorder—Topiramate—epilepsy syndrome	4.73e-05	0.000468	CcSEcCtD
Solifenacin—Oedema peripheral—Topiramate—epilepsy syndrome	4.72e-05	0.000467	CcSEcCtD
Solifenacin—Cough—Pregabalin—epilepsy syndrome	4.72e-05	0.000467	CcSEcCtD
Solifenacin—Pruritus—Phenytoin—epilepsy syndrome	4.71e-05	0.000466	CcSEcCtD
Solifenacin—Connective tissue disorder—Topiramate—epilepsy syndrome	4.71e-05	0.000466	CcSEcCtD
Solifenacin—Nausea—Levetiracetam—epilepsy syndrome	4.71e-05	0.000466	CcSEcCtD
Solifenacin—Rash—Vigabatrin—epilepsy syndrome	4.7e-05	0.000465	CcSEcCtD
Solifenacin—Dizziness—Felbamate—epilepsy syndrome	4.7e-05	0.000465	CcSEcCtD
Solifenacin—Dermatitis—Vigabatrin—epilepsy syndrome	4.69e-05	0.000465	CcSEcCtD
Solifenacin—Urethral disorder—Topiramate—epilepsy syndrome	4.69e-05	0.000465	CcSEcCtD
Solifenacin—Pruritus—Oxcarbazepine—epilepsy syndrome	4.68e-05	0.000464	CcSEcCtD
Solifenacin—Hypersensitivity—Carbamazepine—epilepsy syndrome	4.68e-05	0.000463	CcSEcCtD
Solifenacin—Vision blurred—Gabapentin—epilepsy syndrome	4.67e-05	0.000462	CcSEcCtD
Solifenacin—Headache—Vigabatrin—epilepsy syndrome	4.67e-05	0.000462	CcSEcCtD
Solifenacin—Hypertension—Pregabalin—epilepsy syndrome	4.67e-05	0.000462	CcSEcCtD
Solifenacin—Vomiting—Diazepam—epilepsy syndrome	4.67e-05	0.000462	CcSEcCtD
Solifenacin—Rash—Diazepam—epilepsy syndrome	4.63e-05	0.000458	CcSEcCtD
Solifenacin—Dermatitis—Diazepam—epilepsy syndrome	4.62e-05	0.000458	CcSEcCtD
Solifenacin—Dizziness—Zonisamide—epilepsy syndrome	4.6e-05	0.000455	CcSEcCtD
Solifenacin—Headache—Diazepam—epilepsy syndrome	4.6e-05	0.000455	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	4.57e-05	0.000452	CcSEcCtD
Solifenacin—Asthenia—Carbamazepine—epilepsy syndrome	4.56e-05	0.000451	CcSEcCtD
Solifenacin—Nausea—Fosphenytoin—epilepsy syndrome	4.54e-05	0.00045	CcSEcCtD
Solifenacin—Erythema multiforme—Topiramate—epilepsy syndrome	4.53e-05	0.000448	CcSEcCtD
Solifenacin—Angioedema—Gabapentin—epilepsy syndrome	4.53e-05	0.000448	CcSEcCtD
Solifenacin—Hypersensitivity—Lamotrigine—epilepsy syndrome	4.52e-05	0.000448	CcSEcCtD
Solifenacin—Vomiting—Felbamate—epilepsy syndrome	4.52e-05	0.000447	CcSEcCtD
Solifenacin—Dry mouth—Pregabalin—epilepsy syndrome	4.5e-05	0.000446	CcSEcCtD
Solifenacin—Pruritus—Carbamazepine—epilepsy syndrome	4.49e-05	0.000445	CcSEcCtD
Solifenacin—Rash—Felbamate—epilepsy syndrome	4.48e-05	0.000443	CcSEcCtD
Solifenacin—Eye disorder—Topiramate—epilepsy syndrome	4.48e-05	0.000443	CcSEcCtD
Solifenacin—Dermatitis—Felbamate—epilepsy syndrome	4.47e-05	0.000443	CcSEcCtD
Solifenacin—Headache—Felbamate—epilepsy syndrome	4.45e-05	0.000441	CcSEcCtD
Solifenacin—Confusional state—Pregabalin—epilepsy syndrome	4.45e-05	0.00044	CcSEcCtD
Solifenacin—Cardiac disorder—Topiramate—epilepsy syndrome	4.44e-05	0.00044	CcSEcCtD
Solifenacin—Dizziness—Clonazepam—epilepsy syndrome	4.43e-05	0.000439	CcSEcCtD
Solifenacin—Nausea—Vigabatrin—epilepsy syndrome	4.43e-05	0.000438	CcSEcCtD
Solifenacin—Vomiting—Zonisamide—epilepsy syndrome	4.42e-05	0.000438	CcSEcCtD
Solifenacin—Anaphylactic shock—Pregabalin—epilepsy syndrome	4.41e-05	0.000437	CcSEcCtD
Solifenacin—Asthenia—Lamotrigine—epilepsy syndrome	4.4e-05	0.000436	CcSEcCtD
Solifenacin—Dizziness—Phenytoin—epilepsy syndrome	4.4e-05	0.000436	CcSEcCtD
Solifenacin—Rash—Zonisamide—epilepsy syndrome	4.38e-05	0.000434	CcSEcCtD
Solifenacin—Infection—Pregabalin—epilepsy syndrome	4.38e-05	0.000434	CcSEcCtD
Solifenacin—Palpitations—Gabapentin—epilepsy syndrome	4.38e-05	0.000434	CcSEcCtD
Solifenacin—Dermatitis—Zonisamide—epilepsy syndrome	4.38e-05	0.000434	CcSEcCtD
Solifenacin—Dizziness—Oxcarbazepine—epilepsy syndrome	4.38e-05	0.000433	CcSEcCtD
Solifenacin—Nausea—Diazepam—epilepsy syndrome	4.36e-05	0.000432	CcSEcCtD
Solifenacin—Headache—Zonisamide—epilepsy syndrome	4.35e-05	0.000431	CcSEcCtD
Solifenacin—Angiopathy—Topiramate—epilepsy syndrome	4.34e-05	0.00043	CcSEcCtD
Solifenacin—Pruritus—Lamotrigine—epilepsy syndrome	4.34e-05	0.00043	CcSEcCtD
Solifenacin—Somnolence—Valproic Acid—epilepsy syndrome	4.34e-05	0.000429	CcSEcCtD
Solifenacin—Immune system disorder—Topiramate—epilepsy syndrome	4.33e-05	0.000428	CcSEcCtD
Solifenacin—Nervous system disorder—Pregabalin—epilepsy syndrome	4.33e-05	0.000428	CcSEcCtD
Solifenacin—Cough—Gabapentin—epilepsy syndrome	4.32e-05	0.000428	CcSEcCtD
Solifenacin—Mediastinal disorder—Topiramate—epilepsy syndrome	4.32e-05	0.000427	CcSEcCtD
Solifenacin—Tachycardia—Pregabalin—epilepsy syndrome	4.3e-05	0.000426	CcSEcCtD
Solifenacin—Dyspepsia—Valproic Acid—epilepsy syndrome	4.29e-05	0.000425	CcSEcCtD
Solifenacin—CYP3A4—nervous system—epilepsy syndrome	4.29e-05	0.0134	CbGeAlD
Solifenacin—Skin disorder—Pregabalin—epilepsy syndrome	4.28e-05	0.000424	CcSEcCtD
Solifenacin—Hypertension—Gabapentin—epilepsy syndrome	4.28e-05	0.000424	CcSEcCtD
Solifenacin—Vomiting—Clonazepam—epilepsy syndrome	4.26e-05	0.000422	CcSEcCtD
Solifenacin—Decreased appetite—Valproic Acid—epilepsy syndrome	4.24e-05	0.00042	CcSEcCtD
Solifenacin—Vomiting—Phenytoin—epilepsy syndrome	4.23e-05	0.000419	CcSEcCtD
Solifenacin—Rash—Clonazepam—epilepsy syndrome	4.22e-05	0.000418	CcSEcCtD
Solifenacin—Dermatitis—Clonazepam—epilepsy syndrome	4.22e-05	0.000418	CcSEcCtD
Solifenacin—Nausea—Felbamate—epilepsy syndrome	4.22e-05	0.000418	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	4.21e-05	0.000417	CcSEcCtD
Solifenacin—Vomiting—Oxcarbazepine—epilepsy syndrome	4.21e-05	0.000417	CcSEcCtD
Solifenacin—Fatigue—Valproic Acid—epilepsy syndrome	4.21e-05	0.000416	CcSEcCtD
Solifenacin—Dizziness—Carbamazepine—epilepsy syndrome	4.2e-05	0.000416	CcSEcCtD
Solifenacin—Headache—Clonazepam—epilepsy syndrome	4.2e-05	0.000416	CcSEcCtD
Solifenacin—Rash—Phenytoin—epilepsy syndrome	4.2e-05	0.000415	CcSEcCtD
Solifenacin—Mental disorder—Topiramate—epilepsy syndrome	4.2e-05	0.000415	CcSEcCtD
Solifenacin—Dermatitis—Phenytoin—epilepsy syndrome	4.19e-05	0.000415	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	4.19e-05	0.000415	CcSEcCtD
Solifenacin—Rash—Oxcarbazepine—epilepsy syndrome	4.17e-05	0.000413	CcSEcCtD
Solifenacin—Constipation—Valproic Acid—epilepsy syndrome	4.17e-05	0.000413	CcSEcCtD
Solifenacin—Dermatitis—Oxcarbazepine—epilepsy syndrome	4.17e-05	0.000413	CcSEcCtD
Solifenacin—Headache—Phenytoin—epilepsy syndrome	4.17e-05	0.000413	CcSEcCtD
Solifenacin—Malnutrition—Topiramate—epilepsy syndrome	4.17e-05	0.000413	CcSEcCtD
Solifenacin—Headache—Oxcarbazepine—epilepsy syndrome	4.15e-05	0.000411	CcSEcCtD
Solifenacin—Nausea—Zonisamide—epilepsy syndrome	4.13e-05	0.000409	CcSEcCtD
Solifenacin—CYP3A4—central nervous system—epilepsy syndrome	4.13e-05	0.0129	CbGeAlD
Solifenacin—Dry mouth—Gabapentin—epilepsy syndrome	4.13e-05	0.000409	CcSEcCtD
Solifenacin—Dysgeusia—Topiramate—epilepsy syndrome	4.08e-05	0.000404	CcSEcCtD
Solifenacin—Confusional state—Gabapentin—epilepsy syndrome	4.08e-05	0.000404	CcSEcCtD
Solifenacin—Dizziness—Lamotrigine—epilepsy syndrome	4.06e-05	0.000402	CcSEcCtD
Solifenacin—Anaphylactic shock—Gabapentin—epilepsy syndrome	4.04e-05	0.0004	CcSEcCtD
Solifenacin—Vomiting—Carbamazepine—epilepsy syndrome	4.04e-05	0.0004	CcSEcCtD
Solifenacin—Feeling abnormal—Valproic Acid—epilepsy syndrome	4.02e-05	0.000398	CcSEcCtD
Solifenacin—Infection—Gabapentin—epilepsy syndrome	4.02e-05	0.000398	CcSEcCtD
Solifenacin—Rash—Carbamazepine—epilepsy syndrome	4.01e-05	0.000397	CcSEcCtD
Solifenacin—Dermatitis—Carbamazepine—epilepsy syndrome	4e-05	0.000396	CcSEcCtD
Solifenacin—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.99e-05	0.000395	CcSEcCtD
Solifenacin—Nausea—Clonazepam—epilepsy syndrome	3.98e-05	0.000394	CcSEcCtD
Solifenacin—Headache—Carbamazepine—epilepsy syndrome	3.98e-05	0.000394	CcSEcCtD
Solifenacin—Nervous system disorder—Gabapentin—epilepsy syndrome	3.97e-05	0.000393	CcSEcCtD
Solifenacin—Nausea—Phenytoin—epilepsy syndrome	3.95e-05	0.000391	CcSEcCtD
Solifenacin—Tachycardia—Gabapentin—epilepsy syndrome	3.95e-05	0.000391	CcSEcCtD
Solifenacin—Nausea—Oxcarbazepine—epilepsy syndrome	3.93e-05	0.000389	CcSEcCtD
Solifenacin—Vision blurred—Topiramate—epilepsy syndrome	3.93e-05	0.000389	CcSEcCtD
Solifenacin—Skin disorder—Gabapentin—epilepsy syndrome	3.93e-05	0.000389	CcSEcCtD
Solifenacin—Somnolence—Pregabalin—epilepsy syndrome	3.92e-05	0.000388	CcSEcCtD
Solifenacin—Vomiting—Lamotrigine—epilepsy syndrome	3.9e-05	0.000387	CcSEcCtD
Solifenacin—Urticaria—Valproic Acid—epilepsy syndrome	3.88e-05	0.000384	CcSEcCtD
Solifenacin—Rash—Lamotrigine—epilepsy syndrome	3.87e-05	0.000383	CcSEcCtD
Solifenacin—Dermatitis—Lamotrigine—epilepsy syndrome	3.87e-05	0.000383	CcSEcCtD
Solifenacin—Abdominal pain—Valproic Acid—epilepsy syndrome	3.86e-05	0.000382	CcSEcCtD
Solifenacin—Headache—Lamotrigine—epilepsy syndrome	3.85e-05	0.000381	CcSEcCtD
Solifenacin—Decreased appetite—Pregabalin—epilepsy syndrome	3.83e-05	0.00038	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.81e-05	0.000377	CcSEcCtD
Solifenacin—Fatigue—Pregabalin—epilepsy syndrome	3.8e-05	0.000377	CcSEcCtD
Solifenacin—Nausea—Carbamazepine—epilepsy syndrome	3.77e-05	0.000374	CcSEcCtD
Solifenacin—Constipation—Pregabalin—epilepsy syndrome	3.77e-05	0.000373	CcSEcCtD
Solifenacin—Palpitations—Topiramate—epilepsy syndrome	3.68e-05	0.000365	CcSEcCtD
Solifenacin—Nausea—Lamotrigine—epilepsy syndrome	3.65e-05	0.000361	CcSEcCtD
Solifenacin—Cough—Topiramate—epilepsy syndrome	3.64e-05	0.00036	CcSEcCtD
Solifenacin—Feeling abnormal—Pregabalin—epilepsy syndrome	3.63e-05	0.00036	CcSEcCtD
Solifenacin—Gastrointestinal pain—Pregabalin—epilepsy syndrome	3.61e-05	0.000357	CcSEcCtD
Solifenacin—Hypertension—Topiramate—epilepsy syndrome	3.6e-05	0.000356	CcSEcCtD
Solifenacin—Somnolence—Gabapentin—epilepsy syndrome	3.6e-05	0.000356	CcSEcCtD
Solifenacin—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.59e-05	0.000356	CcSEcCtD
Solifenacin—Dyspepsia—Gabapentin—epilepsy syndrome	3.56e-05	0.000353	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.52e-05	0.000349	CcSEcCtD
Solifenacin—Decreased appetite—Gabapentin—epilepsy syndrome	3.52e-05	0.000348	CcSEcCtD
Solifenacin—Urticaria—Pregabalin—epilepsy syndrome	3.5e-05	0.000347	CcSEcCtD
Solifenacin—Asthenia—Valproic Acid—epilepsy syndrome	3.5e-05	0.000347	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.49e-05	0.000346	CcSEcCtD
Solifenacin—Fatigue—Gabapentin—epilepsy syndrome	3.49e-05	0.000345	CcSEcCtD
Solifenacin—Abdominal pain—Pregabalin—epilepsy syndrome	3.49e-05	0.000345	CcSEcCtD
Solifenacin—Dry mouth—Topiramate—epilepsy syndrome	3.47e-05	0.000344	CcSEcCtD
Solifenacin—Constipation—Gabapentin—epilepsy syndrome	3.46e-05	0.000342	CcSEcCtD
Solifenacin—Pruritus—Valproic Acid—epilepsy syndrome	3.45e-05	0.000342	CcSEcCtD
Solifenacin—Confusional state—Topiramate—epilepsy syndrome	3.43e-05	0.00034	CcSEcCtD
Solifenacin—Infection—Topiramate—epilepsy syndrome	3.38e-05	0.000335	CcSEcCtD
Solifenacin—Nervous system disorder—Topiramate—epilepsy syndrome	3.34e-05	0.00033	CcSEcCtD
Solifenacin—Feeling abnormal—Gabapentin—epilepsy syndrome	3.33e-05	0.00033	CcSEcCtD
Solifenacin—Tachycardia—Topiramate—epilepsy syndrome	3.32e-05	0.000329	CcSEcCtD
Solifenacin—Gastrointestinal pain—Gabapentin—epilepsy syndrome	3.31e-05	0.000327	CcSEcCtD
Solifenacin—Skin disorder—Topiramate—epilepsy syndrome	3.3e-05	0.000327	CcSEcCtD
Solifenacin—Hypersensitivity—Pregabalin—epilepsy syndrome	3.25e-05	0.000322	CcSEcCtD
Solifenacin—Dizziness—Valproic Acid—epilepsy syndrome	3.23e-05	0.000319	CcSEcCtD
Solifenacin—Urticaria—Gabapentin—epilepsy syndrome	3.21e-05	0.000318	CcSEcCtD
Solifenacin—Abdominal pain—Gabapentin—epilepsy syndrome	3.2e-05	0.000317	CcSEcCtD
Solifenacin—Asthenia—Pregabalin—epilepsy syndrome	3.16e-05	0.000313	CcSEcCtD
Solifenacin—Pruritus—Pregabalin—epilepsy syndrome	3.12e-05	0.000309	CcSEcCtD
Solifenacin—Vomiting—Valproic Acid—epilepsy syndrome	3.1e-05	0.000307	CcSEcCtD
Solifenacin—Rash—Valproic Acid—epilepsy syndrome	3.08e-05	0.000305	CcSEcCtD
Solifenacin—Dermatitis—Valproic Acid—epilepsy syndrome	3.07e-05	0.000304	CcSEcCtD
Solifenacin—Headache—Valproic Acid—epilepsy syndrome	3.06e-05	0.000303	CcSEcCtD
Solifenacin—Somnolence—Topiramate—epilepsy syndrome	3.02e-05	0.0003	CcSEcCtD
Solifenacin—Dyspepsia—Topiramate—epilepsy syndrome	2.99e-05	0.000297	CcSEcCtD
Solifenacin—Hypersensitivity—Gabapentin—epilepsy syndrome	2.98e-05	0.000295	CcSEcCtD
Solifenacin—Decreased appetite—Topiramate—epilepsy syndrome	2.96e-05	0.000293	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.94e-05	0.000291	CcSEcCtD
Solifenacin—Fatigue—Topiramate—epilepsy syndrome	2.93e-05	0.00029	CcSEcCtD
Solifenacin—Dizziness—Pregabalin—epilepsy syndrome	2.92e-05	0.000289	CcSEcCtD
Solifenacin—Constipation—Topiramate—epilepsy syndrome	2.91e-05	0.000288	CcSEcCtD
Solifenacin—Asthenia—Gabapentin—epilepsy syndrome	2.9e-05	0.000287	CcSEcCtD
Solifenacin—Nausea—Valproic Acid—epilepsy syndrome	2.9e-05	0.000287	CcSEcCtD
Solifenacin—Pruritus—Gabapentin—epilepsy syndrome	2.86e-05	0.000283	CcSEcCtD
Solifenacin—Vomiting—Pregabalin—epilepsy syndrome	2.8e-05	0.000278	CcSEcCtD
Solifenacin—Feeling abnormal—Topiramate—epilepsy syndrome	2.8e-05	0.000278	CcSEcCtD
Solifenacin—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.78e-05	0.000276	CcSEcCtD
Solifenacin—Rash—Pregabalin—epilepsy syndrome	2.78e-05	0.000275	CcSEcCtD
Solifenacin—Dermatitis—Pregabalin—epilepsy syndrome	2.78e-05	0.000275	CcSEcCtD
Solifenacin—Headache—Pregabalin—epilepsy syndrome	2.76e-05	0.000274	CcSEcCtD
Solifenacin—Urticaria—Topiramate—epilepsy syndrome	2.7e-05	0.000268	CcSEcCtD
Solifenacin—Abdominal pain—Topiramate—epilepsy syndrome	2.69e-05	0.000266	CcSEcCtD
Solifenacin—Dizziness—Gabapentin—epilepsy syndrome	2.67e-05	0.000265	CcSEcCtD
Solifenacin—Nausea—Pregabalin—epilepsy syndrome	2.62e-05	0.000259	CcSEcCtD
Solifenacin—Vomiting—Gabapentin—epilepsy syndrome	2.57e-05	0.000255	CcSEcCtD
Solifenacin—Rash—Gabapentin—epilepsy syndrome	2.55e-05	0.000252	CcSEcCtD
Solifenacin—Dermatitis—Gabapentin—epilepsy syndrome	2.55e-05	0.000252	CcSEcCtD
Solifenacin—Headache—Gabapentin—epilepsy syndrome	2.53e-05	0.000251	CcSEcCtD
Solifenacin—Hypersensitivity—Topiramate—epilepsy syndrome	2.51e-05	0.000248	CcSEcCtD
Solifenacin—Asthenia—Topiramate—epilepsy syndrome	2.44e-05	0.000242	CcSEcCtD
Solifenacin—Pruritus—Topiramate—epilepsy syndrome	2.41e-05	0.000238	CcSEcCtD
Solifenacin—Nausea—Gabapentin—epilepsy syndrome	2.4e-05	0.000238	CcSEcCtD
Solifenacin—Dizziness—Topiramate—epilepsy syndrome	2.25e-05	0.000223	CcSEcCtD
Solifenacin—Vomiting—Topiramate—epilepsy syndrome	2.16e-05	0.000214	CcSEcCtD
Solifenacin—Rash—Topiramate—epilepsy syndrome	2.15e-05	0.000212	CcSEcCtD
Solifenacin—Dermatitis—Topiramate—epilepsy syndrome	2.14e-05	0.000212	CcSEcCtD
Solifenacin—Headache—Topiramate—epilepsy syndrome	2.13e-05	0.000211	CcSEcCtD
Solifenacin—Nausea—Topiramate—epilepsy syndrome	2.02e-05	0.0002	CcSEcCtD
Solifenacin—CHRM2—Signaling Pathways—TSC1—epilepsy syndrome	3.71e-06	6.93e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTK2B—epilepsy syndrome	3.71e-06	6.93e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AGT—epilepsy syndrome	3.7e-06	6.91e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AGT—epilepsy syndrome	3.69e-06	6.89e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NTRK2—epilepsy syndrome	3.65e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SST—epilepsy syndrome	3.65e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR2—epilepsy syndrome	3.65e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AGT—epilepsy syndrome	3.65e-06	6.82e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR2—epilepsy syndrome	3.64e-06	6.8e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SST—epilepsy syndrome	3.64e-06	6.8e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NTRK2—epilepsy syndrome	3.64e-06	6.8e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—YWHAZ—epilepsy syndrome	3.63e-06	6.78e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DUSP6—epilepsy syndrome	3.62e-06	6.77e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—FYN—epilepsy syndrome	3.62e-06	6.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DUSP6—epilepsy syndrome	3.61e-06	6.74e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NTRK2—epilepsy syndrome	3.61e-06	6.74e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR2—epilepsy syndrome	3.61e-06	6.74e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SST—epilepsy syndrome	3.61e-06	6.74e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—H2AFX—epilepsy syndrome	3.6e-06	6.73e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MEF2C—epilepsy syndrome	3.6e-06	6.72e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NGF—epilepsy syndrome	3.59e-06	6.71e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	3.58e-06	6.7e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADRA2A—epilepsy syndrome	3.58e-06	6.68e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DUSP6—epilepsy syndrome	3.58e-06	6.68e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADRA2A—epilepsy syndrome	3.56e-06	6.66e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PLAT—epilepsy syndrome	3.56e-06	6.65e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PLAT—epilepsy syndrome	3.55e-06	6.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADRA2A—epilepsy syndrome	3.53e-06	6.59e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PLAT—epilepsy syndrome	3.51e-06	6.57e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCR5—epilepsy syndrome	3.49e-06	6.52e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	3.49e-06	6.51e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—YWHAZ—epilepsy syndrome	3.48e-06	6.49e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NGF—epilepsy syndrome	3.44e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BDKRB2—epilepsy syndrome	3.44e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL12—epilepsy syndrome	3.44e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—POMC—epilepsy syndrome	3.43e-06	6.41e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BDKRB2—epilepsy syndrome	3.42e-06	6.4e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL12—epilepsy syndrome	3.42e-06	6.4e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PRKCB—epilepsy syndrome	3.42e-06	6.39e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—POMC—epilepsy syndrome	3.42e-06	6.39e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HTR2A—epilepsy syndrome	3.42e-06	6.38e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PRKCB—epilepsy syndrome	3.41e-06	6.37e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6ST—epilepsy syndrome	3.41e-06	6.36e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NT5E—epilepsy syndrome	3.4e-06	6.35e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALAD—epilepsy syndrome	3.4e-06	6.35e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6ST—epilepsy syndrome	3.39e-06	6.34e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL12—epilepsy syndrome	3.39e-06	6.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BDKRB2—epilepsy syndrome	3.39e-06	6.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—POMC—epilepsy syndrome	3.39e-06	6.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PRKCB—epilepsy syndrome	3.38e-06	6.31e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—JUNB—epilepsy syndrome	3.37e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CNR1—epilepsy syndrome	3.37e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6ST—epilepsy syndrome	3.36e-06	6.28e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—JUNB—epilepsy syndrome	3.36e-06	6.28e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CNR1—epilepsy syndrome	3.36e-06	6.28e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PLCB1—epilepsy syndrome	3.36e-06	6.28e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PLCB1—epilepsy syndrome	3.35e-06	6.26e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCR5—epilepsy syndrome	3.34e-06	6.25e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—HMOX1—epilepsy syndrome	3.33e-06	6.22e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—JUNB—epilepsy syndrome	3.33e-06	6.22e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CNR1—epilepsy syndrome	3.33e-06	6.22e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PLCB1—epilepsy syndrome	3.32e-06	6.2e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR7—epilepsy syndrome	3.29e-06	6.15e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CAT—epilepsy syndrome	3.29e-06	6.14e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR7—epilepsy syndrome	3.28e-06	6.13e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HTR2A—epilepsy syndrome	3.27e-06	6.11e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR7—epilepsy syndrome	3.25e-06	6.07e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TSC2—epilepsy syndrome	3.25e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AGT—epilepsy syndrome	3.24e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	3.24e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	3.24e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ABCB1—epilepsy syndrome	3.2e-06	5.97e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HBEGF—epilepsy syndrome	3.19e-06	5.97e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HBEGF—epilepsy syndrome	3.18e-06	5.95e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—APOE—epilepsy syndrome	3.18e-06	5.93e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	3.17e-06	5.93e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HBEGF—epilepsy syndrome	3.15e-06	5.89e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT3—epilepsy syndrome	3.13e-06	5.86e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT3—epilepsy syndrome	3.12e-06	5.84e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—POMC—epilepsy syndrome	3.11e-06	5.82e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KDR—epilepsy syndrome	3.11e-06	5.81e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TSC2—epilepsy syndrome	3.11e-06	5.81e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADSL—epilepsy syndrome	3.11e-06	5.81e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—POMC—epilepsy syndrome	3.11e-06	5.8e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AGT—epilepsy syndrome	3.1e-06	5.8e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT3—epilepsy syndrome	3.09e-06	5.78e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—POMC—epilepsy syndrome	3.07e-06	5.74e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADAM10—epilepsy syndrome	3.06e-06	5.72e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADAM10—epilepsy syndrome	3.05e-06	5.7e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL2—epilepsy syndrome	3.05e-06	5.69e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GLUL—epilepsy syndrome	3.05e-06	5.69e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—APOE—epilepsy syndrome	3.04e-06	5.68e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL2—epilepsy syndrome	3.04e-06	5.68e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADAM10—epilepsy syndrome	3.02e-06	5.65e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL2—epilepsy syndrome	3.01e-06	5.62e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PRKCB—epilepsy syndrome	3e-06	5.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	2.99e-06	5.59e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6ST—epilepsy syndrome	2.98e-06	5.57e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KDR—epilepsy syndrome	2.98e-06	5.57e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GPX1—epilepsy syndrome	2.97e-06	5.55e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—S100B—epilepsy syndrome	2.9e-06	5.41e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—S100B—epilepsy syndrome	2.89e-06	5.39e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PRKCB—epilepsy syndrome	2.87e-06	5.36e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SOCS3—epilepsy syndrome	2.87e-06	5.36e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDC42—epilepsy syndrome	2.86e-06	5.34e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—S100B—epilepsy syndrome	2.86e-06	5.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SOCS3—epilepsy syndrome	2.86e-06	5.34e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6ST—epilepsy syndrome	2.86e-06	5.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDC42—epilepsy syndrome	2.85e-06	5.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SOCS3—epilepsy syndrome	2.83e-06	5.29e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDC42—epilepsy syndrome	2.82e-06	5.27e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	2.8e-06	5.23e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AVP—epilepsy syndrome	2.77e-06	5.17e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AVP—epilepsy syndrome	2.76e-06	5.16e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AVP—epilepsy syndrome	2.73e-06	5.11e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—POMC—epilepsy syndrome	2.73e-06	5.1e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AQP1—epilepsy syndrome	2.72e-06	5.07e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL2—epilepsy syndrome	2.67e-06	4.99e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HES1—epilepsy syndrome	2.62e-06	4.89e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—POMC—epilepsy syndrome	2.61e-06	4.88e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HES1—epilepsy syndrome	2.61e-06	4.88e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AGT—epilepsy syndrome	2.61e-06	4.87e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HES1—epilepsy syndrome	2.58e-06	4.83e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL2—epilepsy syndrome	2.56e-06	4.78e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APOE—epilepsy syndrome	2.55e-06	4.77e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FYN—epilepsy syndrome	2.55e-06	4.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FYN—epilepsy syndrome	2.54e-06	4.74e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—H2AFX—epilepsy syndrome	2.54e-06	4.74e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MEF2C—epilepsy syndrome	2.53e-06	4.73e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—H2AFX—epilepsy syndrome	2.53e-06	4.72e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MEF2C—epilepsy syndrome	2.52e-06	4.72e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FYN—epilepsy syndrome	2.51e-06	4.7e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—H2AFX—epilepsy syndrome	2.5e-06	4.68e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MEF2C—epilepsy syndrome	2.5e-06	4.67e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	2.46e-06	4.59e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	2.46e-06	4.59e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	2.45e-06	4.57e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—YWHAZ—epilepsy syndrome	2.44e-06	4.56e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NGF—epilepsy syndrome	2.42e-06	4.52e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—YWHAZ—epilepsy syndrome	2.42e-06	4.51e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—FGF2—epilepsy syndrome	2.41e-06	4.51e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NGF—epilepsy syndrome	2.41e-06	4.51e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NGF—epilepsy syndrome	2.39e-06	4.46e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR5—epilepsy syndrome	2.35e-06	4.4e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR5—epilepsy syndrome	2.35e-06	4.38e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR5—epilepsy syndrome	2.32e-06	4.34e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—FGF2—epilepsy syndrome	2.31e-06	4.32e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR2A—epilepsy syndrome	2.3e-06	4.3e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR2A—epilepsy syndrome	2.3e-06	4.29e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR2A—epilepsy syndrome	2.27e-06	4.25e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RELA—epilepsy syndrome	2.24e-06	4.18e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MTOR—epilepsy syndrome	2.2e-06	4.1e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—POMC—epilepsy syndrome	2.19e-06	4.1e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TSC2—epilepsy syndrome	2.19e-06	4.09e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGT—epilepsy syndrome	2.19e-06	4.08e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TSC2—epilepsy syndrome	2.18e-06	4.08e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGT—epilepsy syndrome	2.18e-06	4.07e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TSC2—epilepsy syndrome	2.16e-06	4.04e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGT—epilepsy syndrome	2.16e-06	4.03e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RELA—epilepsy syndrome	2.15e-06	4.01e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOE—epilepsy syndrome	2.14e-06	4e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOE—epilepsy syndrome	2.14e-06	3.99e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOE—epilepsy syndrome	2.11e-06	3.95e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MTOR—epilepsy syndrome	2.1e-06	3.93e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KDR—epilepsy syndrome	2.1e-06	3.92e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KDR—epilepsy syndrome	2.09e-06	3.91e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KDR—epilepsy syndrome	2.07e-06	3.87e-05	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AKT1—epilepsy syndrome	2.04e-06	3.81e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CASP3—epilepsy syndrome	2.02e-06	3.77e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PRKCB—epilepsy syndrome	2.02e-06	3.77e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PRKCB—epilepsy syndrome	2.01e-06	3.76e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6ST—epilepsy syndrome	2.01e-06	3.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6ST—epilepsy syndrome	2.01e-06	3.75e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	2e-06	3.74e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—epilepsy syndrome	2e-06	3.74e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PRKCB—epilepsy syndrome	1.99e-06	3.72e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6ST—epilepsy syndrome	1.99e-06	3.71e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—JUN—epilepsy syndrome	1.96e-06	3.67e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—epilepsy syndrome	1.95e-06	3.65e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	1.95e-06	3.65e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	1.94e-06	3.62e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CASP3—epilepsy syndrome	1.93e-06	3.61e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—epilepsy syndrome	1.91e-06	3.57e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—JUN—epilepsy syndrome	1.88e-06	3.51e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—epilepsy syndrome	1.85e-06	3.46e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—POMC—epilepsy syndrome	1.84e-06	3.44e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—POMC—epilepsy syndrome	1.83e-06	3.43e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—epilepsy syndrome	1.83e-06	3.42e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—POMC—epilepsy syndrome	1.82e-06	3.39e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL2—epilepsy syndrome	1.8e-06	3.36e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL2—epilepsy syndrome	1.79e-06	3.35e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL2—epilepsy syndrome	1.78e-06	3.32e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—epilepsy syndrome	1.77e-06	3.31e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SRC—epilepsy syndrome	1.76e-06	3.29e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.75e-06	3.27e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—epilepsy syndrome	1.75e-06	3.27e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—epilepsy syndrome	1.71e-06	3.2e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SRC—epilepsy syndrome	1.69e-06	3.15e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.67e-06	3.11e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.66e-06	3.1e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—epilepsy syndrome	1.64e-06	3.07e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FGF2—epilepsy syndrome	1.63e-06	3.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FGF2—epilepsy syndrome	1.62e-06	3.03e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGF2—epilepsy syndrome	1.61e-06	3e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	1.58e-06	2.96e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	1.57e-06	2.92e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TH—epilepsy syndrome	1.56e-06	2.91e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RELA—epilepsy syndrome	1.51e-06	2.82e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RELA—epilepsy syndrome	1.51e-06	2.81e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RELA—epilepsy syndrome	1.49e-06	2.79e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MTOR—epilepsy syndrome	1.48e-06	2.77e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MTOR—epilepsy syndrome	1.48e-06	2.76e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MTOR—epilepsy syndrome	1.46e-06	2.73e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.38e-06	2.57e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—epilepsy syndrome	1.37e-06	2.56e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CASP3—epilepsy syndrome	1.36e-06	2.55e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CASP3—epilepsy syndrome	1.36e-06	2.54e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—epilepsy syndrome	1.36e-06	2.54e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CASP3—epilepsy syndrome	1.34e-06	2.51e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—JUN—epilepsy syndrome	1.32e-06	2.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—JUN—epilepsy syndrome	1.32e-06	2.46e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—JUN—epilepsy syndrome	1.31e-06	2.44e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	1.3e-06	2.43e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—epilepsy syndrome	1.29e-06	2.41e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CAT—epilepsy syndrome	1.28e-06	2.4e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—epilepsy syndrome	1.28e-06	2.4e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—epilepsy syndrome	1.27e-06	2.37e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	1.25e-06	2.33e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—epilepsy syndrome	1.25e-06	2.33e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—epilepsy syndrome	1.24e-06	2.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—epilepsy syndrome	1.23e-06	2.3e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SRC—epilepsy syndrome	1.19e-06	2.22e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SRC—epilepsy syndrome	1.18e-06	2.21e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SRC—epilepsy syndrome	1.17e-06	2.19e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPX1—epilepsy syndrome	1.16e-06	2.17e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—epilepsy syndrome	1.16e-06	2.16e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—epilepsy syndrome	1.15e-06	2.15e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—epilepsy syndrome	1.14e-06	2.13e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—epilepsy syndrome	1.09e-06	2.04e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—epilepsy syndrome	1.05e-06	1.96e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AGT—epilepsy syndrome	1.02e-06	1.9e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOE—epilepsy syndrome	9.98e-07	1.86e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—epilepsy syndrome	8.79e-07	1.64e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—POMC—epilepsy syndrome	8.58e-07	1.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—epilepsy syndrome	7.82e-07	1.46e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—epilepsy syndrome	7.38e-07	1.38e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—epilepsy syndrome	7.35e-07	1.37e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—epilepsy syndrome	7.28e-07	1.36e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	6.84e-07	1.28e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—epilepsy syndrome	3.44e-07	6.42e-06	CbGpPWpGaD
